3Sixty Biopharmaceuticals (Pty) Ltd is at varying stages of launching and bringing to market product technologies that respond to some of mankind’s most challenging disease; these include
This portfolio is anchored around anti-retrovirals (ARVs) drugs for HIV and Tuberculosis (TB). ARVs with unique compelling benefits targeting poorly met clinical needs with a strong focus on improving demographic relevance are in pre-commercialisation phase (i.e. phase IV clinical trials). The company focus on TB is on treatment shortening using novel drug delivery systems.
A variety of skin conditions are pursued using a combination of new active pharmaceutical ingredients coupled with new to the world delivery systems. Clinical trials are in final stages.